跳至主要内容
临床试验/NCT01914692
NCT01914692已完成4 期

Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study

First Affiliated Hospital, Sun Yat-Sen University0 个研究点目标入组 2 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
2
主要终点
fistula of pancreas

研究概览

简要总结

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • More than eighteen years old
  • Gastric cancer diagnosed by pathological examination
  • Be given informed consent
  • Without diabetes/hyperthyroidism/Damages of functions of heart, liver and kidney/Systemic Infection/immunodeficiency

排除标准

  • Contraindication of vascular puncture operation
  • Patients who refused to take part in the programe
  • Poor compliance of treatment
  • Malnutrition,BMI<18
  • with pancreatectomy

研究组 & 干预措施

Somatostatin group

Experimental

Patients with Advanced Gastric Cancer After D2 Lymph Node Dissection accept the Somatostatin medical therapy.

干预措施: Somatostatin (Drug)

结局指标

主要结局

fistula of pancreas

时间窗: one year

number of patients

次要结局

  • infection of incisional wound(one year)
  • amount of bleeding(six months)
  • seroperitoneum(six months)

研究者

发起方
First Affiliated Hospital, Sun Yat-Sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wang Shaochuan

Postgraduate

First Affiliated Hospital, Sun Yat-Sen University

相似试验